View Older Stories View More Recent Stories

Sep 20, 2016 06:59AM Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio
Sep 20, 2016 06:59AM European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer
Sep 7, 2016 11:17AM Bristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27
Sep 7, 2016 10:41AM Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
Sep 7, 2016 06:59AM Bristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research
Sep 6, 2016 12:14PM Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Sep 6, 2016 07:00AM Bristol-Myers Squibb (BMY) Receives European Commission Approval of ORENCIA
Sep 6, 2016 06:59AM European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treate
Aug 31, 2016 07:05PM Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights
Aug 23, 2016 07:00AM Bristol-Myers Squibb (BMY), Pfizer (PFE) Will Present New Eliquis Data at ESC Congress 2016
Aug 23, 2016 06:59AM Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016
Aug 5, 2016 08:21AM Bristol-Myers Squibb (BMY) Says CheckMate -026 Trial for Opdivo Missed Primary Endpoint
Aug 5, 2016 08:20AM Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer
Aug 3, 2016 04:15PM Bristol-Myers Squibb Announces Dividend
Jul 28, 2016 06:59AM Bristol-Myers Squibb Reports Second Quarter Financial Results
Jul 26, 2016 07:00AM Bristol-Myers Squibb (BMY), Janssen Enter New Immuno-Oncology-Focused Research Collaboration
Jul 26, 2016 06:59AM Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer
Jul 25, 2016 11:00AM Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head
Jul 25, 2016 07:00AM AbbVie (ABBV), Bristol-Myers Squibb (BMY) to Collaborate on Rova-T + Opdivo Combo
Jul 25, 2016 06:59AM CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in
Jul 25, 2016 06:59AM AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Jul 25, 2016 06:59AM AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Jul 20, 2016 07:00AM Bristol-Myers Squibb (BMY) Announces Commercial Launch of Orencia ClickJect Autoinjector for RA
Jul 20, 2016 06:59AM Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis
Jul 20, 2016 06:59AM Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcutaneous Autoinjector, for Adults with Moderate to Severe Rheumatoid Arthritis
Jul 18, 2016 07:01AM Bristol-Myers Squibb (BMY) Announces FDA, EMA Acceptance of Opdivo Apps for Usage in SCCHN
Jul 18, 2016 06:59AM Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Jul 5, 2016 06:59AM Bristol-Myers Squibb (BMY) Acquires Cormorant Pharma in ~$520M Deal
Jul 5, 2016 06:59AM Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Jun 30, 2016 07:00AM Bristol-Myers Squibb (BMY), PsiOxus Enter Enadenotucirev + Opdivo Combo in Tumors Evaluation Collaboration
Jun 30, 2016 06:59AM Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
Jun 30, 2016 06:59AM Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
Jun 27, 2016 07:00AM Bristol-Myers Squibb's (BMY) Opdivo Granted FDA Breakthrough Therapy Designation in Adv. Bladder Cancer
Jun 27, 2016 06:59AM Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer
Jun 24, 2016 04:10PM Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola
Jun 20, 2016 04:15PM Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer
Jun 10, 2016 02:30AM New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial
Jun 9, 2016 10:00AM Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28
Jun 9, 2016 07:00AM Bristol-Myers Squibb (BMY) Will Present New Opdivo, Empliciti Data at EHA Congress
Jun 9, 2016 06:59AM Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers at the 21st Congress of the European Hematology Assoc
Jun 8, 2016 07:50AM Bristol-Myers Squibb (BMY) Plans to Present New RA Data at EULAR 2016; Will Include anti-CCP and RF Biomarker Data
Jun 8, 2016 07:48AM Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of Rheumatology (EULAR 2016)
Jun 7, 2016 04:15PM Bristol-Myers Squibb Announces Dividend
Jun 7, 2016 06:59AM Bristol-Myers Squibb and MD Anderson Announce New Research Collaboration in Immuno-Oncology Focused on Lung Cancer
Jun 6, 2016 06:59AM Long-Term Data from Two Trials Evaluating the Opdivo® (nivolumab) and Yervoy® (ipilimumab) Regimen in Advanced Melanoma Continues to Validate Bristol-Myers Squibb’s Immuno-Oncology Combination App
Jun 6, 2016 06:24AM Bristol-Myers Squibb (BMY) Issues Strong Data from Opdivo Combo Phase 2 in Metastatic Colorectal Cancer
Jun 6, 2016 06:19AM Bristol-Myers Squibb (BMY) Announces Encouraging L-T OS Data for Opdivo in Advanced RCC
Jun 5, 2016 11:24AM Long-Term Survival and Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting
Jun 5, 2016 09:00AM First Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (ipilimumab) Demonstrates Encouraging Clinical Activity in MSI-High Metastatic
Jun 5, 2016 08:06AM Promising Response Rates with Opdivo® (nivolumab) Observed in Advanced Form of Bladder Cancer from Phase 1/2 Study CheckMate -032
View More Recent Stories View Older Stories